Literature DB >> 20406183

Histone deacetylation and motor neuron degeneration.

S Schmalbach1, S Petri.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with progressive muscular wasting and paralysis due to loss of motor neurons in the primary motor cortex, brainstem and spinal cord. Alterations of transcriptional activity due to an unbalance of the activity of histone acetyl transferases (HAT) and histone deacetylases (HDACs) have been described in a variety of neurodegenerative conditions in vitro and in vivo. HDACs can be grouped into four different classes with distinct cellular localization and functions. HDAC inhibitors have recently been discovered as potential neuroprotective drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A major limitation, however, lies in the broad spectrum of action of currently available HDAC inhibitors causing a variety of toxic side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406183     DOI: 10.2174/187152710791292684

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  6 in total

1.  The preclinical discovery of amyotrophic lateral sclerosis drugs.

Authors:  Marcie A Glicksman
Journal:  Expert Opin Drug Discov       Date:  2011-10-25       Impact factor: 6.098

2.  Class I HDAC imaging using [ (3)H]CI-994 autoradiography.

Authors:  Yajie Wang; Yan-Ling Zhang; Krista Hennig; Jennifer P Gale; Yijia Hong; Anna Cha; Misha Riley; Florence Wagner; Stephen J Haggarty; Edward Holson; Jacob Hooker
Journal:  Epigenetics       Date:  2013-06-11       Impact factor: 4.528

Review 3.  Small molecule inhibitors of zinc-dependent histone deacetylases.

Authors:  Florence F Wagner; Michel Weїwer; Michael C Lewis; Edward B Holson
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

4.  Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord.

Authors:  Dong Liu; Chaoxu Liu; Junqiang Li; Kazem Azadzoi; Yun Yang; Zhou Fei; Kefeng Dou; Neil W Kowall; Han-Pil Choi; Fernando Vieira; Jing-Hua Yang
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

5.  Acetylation state of RelA modulated by epigenetic drugs prolongs survival and induces a neuroprotective effect on ALS murine model.

Authors:  Lorenzo Schiaffino; Roberta Bonafede; Ilaria Scambi; Edoardo Parrella; Marina Pizzi; Raffaella Mariotti
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

6.  Tissue-specific deregulation of selected HDACs characterizes ALS progression in mouse models: pharmacological characterization of SIRT1 and SIRT2 pathways.

Authors:  C Valle; I Salvatori; V Gerbino; S Rossi; L Palamiuc; F René; M T Carrì
Journal:  Cell Death Dis       Date:  2014-06-19       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.